Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 3Graft vs Host Disease 3Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myocarditis 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 7Etoposide 5Prednisone 4Doxorubicin 4Vincristine 3romidepsin 2pembrolizumab 2etoposide phosphate 2duvelisib 2Melphalan 2Brentuximab Vedotin 2Azacitidine 210-propargyl-10-deazaaminopterin 2tazemetostat 1sodium-iodide symporter 1ruxolitinib 1prednylidene 1glofitamab 1fludarabine phosphate 1fludarabine 1deltacortene 1cemiplimab 1brincidofovir 1belinostat 1X-Rays 1Whole-Body Irradiation 1Valganciclovir 1Therapeutics 1Tacrolimus 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoblastic Lymphadenopathy × Abatacept × 1 year × Clear all
NCT07388563 2026-05-08

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Suspended
20 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡